Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/09/01 11:01:17」(JST)

wiki en

Basiliximab (trade name Simulect) is a chimeric mouse-human monoclonal antibody to the α chain (CD25) of the IL-2 receptor of T cells. It is used to prevent rejection in organ transplantation, especially in kidney transplants. It is a Novartis product and was approved by the Food and Drug Administration (FDA) in 1998.

Uses

Basiliximab is an immunosuppresant agent used to prevent immediate transplant rejection in people who are receiving kidney transplants, in combination with other agents.^[1] It has been reported that some cases of Lichen Planus have been successfully treated with Basiliximab as an alternative therapy to Cyclosporine, with a dose of 20 mg every 4 days. No short-term side effects have been reported ^[2]

Mechanism of action

Basiliximab competes with IL-2 to bind to the alpha chain subunit of the IL2 receptor on the surface of the activated T lymphocytes and thus prevents the receptor from signaling. This prevents T cells from replicating and also from activating B cells, which are responsible for the production of antibodies, which would bind to the transplanted organ and stimulate an immune response against the transplant.^[3]^[4]

Physical and chemical properties

It is a chimeric CD25 monoclonal antibody of the IgG1 isotype.^[3]^[4]

History

It is a Novartis product and was approved by the Food and Drug Administration (FDA) in 1998.^[4]^[5]

References and notes

^ MedlinePlus. Last Revised - June 15, 2012 Basiliximab Injection
^ A.D. Katsambas, T.M. Lotti European handbook of dermatological treatments 2nd edition, 2003, page 291, ISBN 3-540-00878-0
^ ^a ^b Hardinger KL, Brennan DC, Klein CL. Selection of induction therapy in kidney transplantation. Transpl Int. 2013 Jul;26(7):662-72. PMID 23279211
^ ^a ^b ^c Basiliximab label
^ Waldman, Thomas A. (2003). Immunotherapy: past, present and future. Nature Medicine 9, 269-277.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 成人における肝移植：免疫抑制の概要 liver transplantation in adults overview of immunosuppression
2. Induction immunosuppressive therapy in renal transplantation in adults
3. 肺移植後の免疫抑制の導入 induction immunosuppression following lung transplantation
4. 急性移植片対宿主病の治療 treatment of acute graft versus host disease
5. 心臓移植における免疫抑制療法の導入および維持 induction and maintenance of immunosuppressive therapy in cardiac transplantation

English Journal

Renal transplantation in human immunodeficiency virus (HIV)-positive children.

McCulloch MI1, Kala UK.Author information 1Department of Paediatrics, Red Cross Children's Hospital, University of Cape Town, Cape Town, South Africa, mignonmcculloch@yahoo.co.uk.AbstractRenal transplantation is being performed in adult human immunodeficiency virus (HIV)-positive patients and increasingly in paediatric patients as well. A multidisciplinary team involving an infectious disease professional is required to assist with HIV viral-load monitoring and in choosing the most appropriate highly active antiretroviral therapy (HAART). Drug interactions complicate immunosuppressant therapy and require careful management. The acute rejection rates appear to be similar in adults to those in noninfective transplant recipients. Induction with basiliximab and calcineurin-based immunosuppression appears to be safe and effective in these recipients. Prophylaxis is advised for a variety of infections and may need life-long administration, especially in children. Organ shortage remains a significant problem, and kidneys from deceased HIV-positive donors have been used successfully in a small study population. Overall, with careful planning and close follow-up, successful renal transplantation for paediatric HIV-infected recipients is possible.
Pediatric nephrology (Berlin, Germany).Pediatr Nephrol.2014 Apr 2. [Epub ahead of print]
Renal transplantation is being performed in adult human immunodeficiency virus (HIV)-positive patients and increasingly in paediatric patients as well. A multidisciplinary team involving an infectious disease professional is required to assist with HIV viral-load monitoring and in choosing the most
PMID 24691821

Acute polyarthritis immediately after kidney transplantation: A medication-induced rheumatoid arthritis flare?

Brumby C1, Huang L, Lee D, McMahon L.Author information 1Department of Renal Medicine, Box Hill Hospital, Eastern Health, Melbourne, Victoria, Australia.AbstractA patient with known steroid-dependent rheumatoid arthritis (RA) developed an acute symmetrical polyarthropathy of small and medium-sized joints associated with markedly elevated inflammatory markers suggestive of RA flare, on day 4 after deceased-donor renal transplantation. The patient received standard induction immunosuppression with methylprednisolone and basiliximab, and had commenced prednisolone, tacrolimus and mycophenolate mofetil. Serological investigations and joint aspirate to exclude infective causes and crystal arthropathy were unremarkable. High-dose prednisolone (50 mg daily) resulted in partial but unsustained symptomatic improvement. On suspicion of a medication-related adverse event, tacrolimus and mycophenolate mofetil were changed to cyclosporine A and azathioprine on day 16. This was followed by rapid improvement in symptoms and normalization of inflammatory markers. Unexpected sequelae in the early post-transplantation period create diagnostic and management challenges. Medication-related adverse events are not uncommon, and we speculate in this case on the potential for medication-induced immune system dysregulation stimulating disease activity in a chronic autoimmune condition after introduction of new immunosuppressants.
Nephrology (Carlton, Vic.).Nephrology (Carlton).2014 Apr;19 Suppl 1:2-5. doi: 10.1111/nep.12190.
A patient with known steroid-dependent rheumatoid arthritis (RA) developed an acute symmetrical polyarthropathy of small and medium-sized joints associated with markedly elevated inflammatory markers suggestive of RA flare, on day 4 after deceased-donor renal transplantation. The patient received st
PMID 24467783

Is basiliximab induction, a novel risk factor for new onset diabetes after transplantation for living donor renal allograft recipients?

Prasad N1, Gurjer D, Bhadauria D, Gupta A, Srivastava A, Kaul A, Jaiswal A, Yadav B, Yadav S, Sharma RK.Author information 1Department of Nephrology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.AbstractAIM: It was found that, by affecting populations of T lymphocytes and regulatory T cells, basiliximab also indirectly affects pancreatic β-cell function and glucose homeostasis.
Nephrology (Carlton, Vic.).Nephrology (Carlton).2014 Apr;19(4):244-50. doi: 10.1111/nep.12209.
AIM: It was found that, by affecting populations of T lymphocytes and regulatory T cells, basiliximab also indirectly affects pancreatic β-cell function and glucose homeostasis.METHODS: In this prospective observational study, we included all renal transplant recipients from 1 July 2007 to 31 July
PMID 24447227

Japanese Journal

Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients

加藤容二郎
東京女子医科大学雑誌 83(2), 129-130, 2013-04-25
NAID 120005302574

生体腎移植後,著明な高尿酸血症と急性腎障害を呈した1例

中澤成晃,今村亮一,山本致之 [他],林拓自,谷川剛,藤田和利,細見昌弘,山口誓司
泌尿器科紀要 = Acta urologica Japonica 59(2), 103-106, 2013-02
… We used tacrolimus extended release (0.15 mg/kg/day), mizoribine (MZR) (12 mg/kg/day), prednisolone and basiliximab as immunosuppressants. …
NAID 120005244236

術前に診断されずに腎移植を行い,術後21日目に皮膚癌と診断された1例

福本亮,惣田哲次,林哲也 [他],岡大三,藤本宜正,小出卓生,馬渕恵理子,池上隆太,西尾優志,松下哲也
泌尿器科紀要 58(9), 503-506, 2012-09
… The immunosuppressive regimen consisted of tacrolimus, mycophenolate mofetil, steroid and basiliximab. …
NAID 40019429546

Related Pictures

★リンクテーブル★

リンク元	「mab」「バシリキシマブ」

「mab」

Basiliximab^?
Monoclonal antibody
Type	Whole antibody
Source	Chimeric (mouse/human)
Target	CD25
Clinical data
Trade names	Simulect
AHFS/Drugs.com	monograph
Pregnancy; category	AU: D; US: B (No risk in non-human studies);
Pharmacokinetic data
Biological half-life	7.2 days
Identifiers
CAS Registry Number	152923-56-3
ATC code	L04AC02
DrugBank	DB00074
UNII	9927MT646M
ChEMBL	CHEMBL1201439
Chemical data
Formula	C6378H9844N1698O1997S48
Molecular mass	143801.3 g/mol
(what is this?) (verify)